FDA Approves DATROWAY® for Advanced HR+/HER2- Breast Cancer
Trop-2-directed antibody-drug conjugateA new breast cancer treatment option
The United States Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) on January 17, 2025, for adults with hormone receptor-positive (HR+), HER2-negative breast cancer that is unresectable or metastatic and has already been treated with both endocrine therapy and chemotherapy.
What is DATROWAY?
DATROWAY is a Trop-2-directed antibody-drug conjugate that delivers a chemotherapy payload directly to cancer cells. It was developed by Daiichi Sankyo, Inc.
Administration
DATROWAY is administered via IV infusion once every 3 weeks.
Clinical Trial Snapshot
- Trial Name: TROPION-Breast01
- Patients: 732 (across 20 countries; 59 from the U.S.)
- Design: Compared DATROWAY vs. chemotherapy
- Key Results:
- Progression-Free Survival (PFS):
- DATROWAY: 6.9 months
- Chemotherapy: 4.9 months
- Also showed improved response rates and duration of response.
Potential Side Effects
DATROWAY may cause:
- Severe lung problems, including life-threatening or fatal interstitial lung disease (ILD)
- Mouth sores, eye irritation, keratitis
- Risk to unborn babies
Most common side effects include:
- Mouth ulcers, nausea, fatigue
- Low white/red blood cell counts, hair loss
- Constipation, dry eyes, liver enzyme elevation
Summary
DATROWAY offers a new treatment option for patients with difficult-to-treat HR+/HER2- breast cancer, showing better cancer control than standard chemo — but it carries significant risks that must be carefully managed.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
A Dangerous and Unapproved Drug Sold as a “Cure”
The dangers of tianeptine FDA warns that tianeptine is sold online and even at gas stations as a supposed treatment for depression, anxiety, pain, and opioid withdrawal. But don’t be fooled — this drug is not approved by the FDA for any medical use in the U.S. and has...
Beware of False “Cures” for Autism
Unapproved and Potentially Harmful Products Autism Spectrum Disorder (ASD) affects about 1 in 68 children, and while early behavioral therapies can help improve symptoms, there is no cure for autism. Unfortunately, some companies promote unproven products that falsely...
Formaldehyde in Hair Smoothing Products: Know the Risks
Know the Risks Before You Straighten Thinking of straightening or smoothing your hair? Many salon hair treatments release formaldehyde gas — a known human carcinogen — when heated. This chemical can pose serious short- and long-term health risks to both clients and...